Ocular Therapeutix (OCUL) Retained Earnings (2013 - 2026)

Ocular Therapeutix's Retained Earnings history runs 14 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 30.41% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 30.41% YoY), while the FY2025 annual figure was -$1.2 billion, down 29.84% from the prior year.
• Retained Earnings was -$1.2 billion for Q1 2026 at Ocular Therapeutix, down from -$1.2 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$558.3 million in Q1 2022 to a low of -$1.2 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$812.4 million across 5 years, with a median of -$762.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings declined 4.14% in 2022, then slumped 30.41% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$616.8 million in 2022, then retreated by 13.09% to -$697.6 million in 2023, then retreated by 27.74% to -$891.1 million in 2024, then decreased by 29.84% to -$1.2 billion in 2025, then declined by 7.66% to -$1.2 billion in 2026.
• The last three Retained Earnings figures came in at -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.